Loading...
Indian Pharmaceutical Exporter · Other Specialist · $2.0M Total Trade · DGFT Verified
Chandra Bhagat Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $2.0M across 9 products in 6 therapeutic categories. Based on 81 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Immunoglobulin ($950.0K), Trastuzumab ($300.0K), Guaifenesin ($283.1K).
Chandra Bhagat Pharma Limited, established in 1944, is a Mumbai-based pharmaceutical company specializing in the marketing of critical care and healthcare products both domestically and internationally. The company offers a diverse range of pharmaceutical formulations, including intravenous and intramuscular injections, tablets, and capsules, across various therapeutic categories such as oncology, antibiotics, anesthesia, hormones, orthopedics, cardiology, and more. These products are distributed under the company's own brand to hospitals and healthcare centers.
Incorporated as a private limited company on March 10, 2003, Chandra Bhagat Pharma Limited transitioned to a public limited company on March 20, 2019. The company's authorized capital stands at ₹85 million, with a paid-up capital of ₹75.45 million. As of January 10, 2026, the company employs approximately 40 individuals. The registered office is located at 323-F Bhagat Bhuvan, Dr. Ambedkar Road, Matunga (East), Mumbai, Maharashtra, India, 400019.
Chandra Bhagat Pharma Limited operates across 6 therapeutic categories, with Other (48.1%), Advanced Oncology (18.3%), Respiratory & OTC (14.3%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 93% of total exports.
Other
1 products · 48.1% · $950.0K
Advanced Oncology
4 products · 18.3% · $361.8K
Respiratory & OTC
1 products · 14.3% · $283.1K
Immunosuppressants
1 products · 7.9% · $156.2K
Cardiovascular
1 products · 7.0% · $139.3K
Advanced Antibiotics
Chandra Bhagat Pharma Limited exports 9 pharmaceutical products across 6 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Immunoglobulin | Other | $950.0K | 19 | 0.5% |
Headquarters, ownership, manufacturing facilities, and key leadership
Chandra Bhagat Pharma Limited, established in 1944, is a Mumbai-based pharmaceutical company specializing in the marketing of critical care and healthcare products both domestically and internationally. The company offers a diverse range of pharmaceutical formulations, including intravenous and intramuscular injections, tablets, and capsules, across various therapeutic categories such as oncology, antibiotics, anesthesia, hormones, orthopedics, cardiology, and more. These products are distributed under the company's own brand to hospitals and healthcare centers.
Incorporated as a private limited company on March 10, 2003, Chandra Bhagat Pharma Limited transitioned to a public limited company on March 20, 2019. The company's authorized capital stands at ₹85 million, with a paid-up capital of ₹75.45 million. As of January 10, 2026, the company employs approximately 40 individuals. The registered office is located at 323-F Bhagat Bhuvan, Dr. Ambedkar Road, Matunga (East), Mumbai, Maharashtra, India, 400019.
Chandra Bhagat Pharma Limited operates manufacturing facilities through contract manufacturing arrangements, focusing on the production of pharmaceutical formulations. The company specializes in a range of products, including intravenous and intramuscular injections, tablets, and capsules, catering to both domestic and international markets. By outsourcing manufacturing to third-party contract manufacturers, Chandra Bhagat Pharma Limited ensures compliance with regulatory standards and maintains flexibility in production capacity.
1 products · 4.3% · $85.5K
| 7 |
| 2 | Trastuzumab | Advanced Oncology | $300.0K | 6 | 0.4% | 7 |
| 3 | Guaifenesin | Respiratory & OTC | $283.1K | 9 | 1.1% | 13 |
| 4 | Cyclosporine | Immunosuppressants | $156.2K | 12 | 1.3% | 10 |
| 5 | Warfarin | Cardiovascular | $139.3K | 16 | 1.9% | 7 |
| 6 | Fosfomycin | Advanced Antibiotics | $85.5K | 4 | 0.7% | 7 |
| 7 | Fludarabine | Advanced Oncology | $24.3K | 4 | 0.8% | 7 |
| 8 | Actinomycin | Advanced Oncology | $19.2K | 6 | 0.7% | 11 |
| 9 | Mitoxantrone | Advanced Oncology | $18.3K | 5 | 1.0% | 5 |
Chandra Bhagat Pharma Limited exports 9 pharmaceutical products across 6 therapeutic categories with a total export value of $2.0M. The top category is Other (48.1% of portfolio), followed by Advanced Oncology (18.3%), indicating a concentrated portfolio with the top 5 products accounting for 92.5% of total export value.
Shipment-level records, pricing & buyer contacts for Chandra Bhagat Pharma Limited.
Request DemoThe leadership team at Chandra Bhagat Pharma Limited comprises:
Regulated market presence, emerging market penetration, and geographic strategy
Chandra Bhagat Pharma Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary approvals from the U.S. Food and Drug Administration (FDA) for its formulations, enabling manufacturing through contract manufacturers. Additionally, Chandra Bhagat Pharma Limited ensures that its products are sourced from qualified factories with a minimum of World Health Organization Good Manufacturing Practice (WHO GMP) approvals, facilitating access to these regulated markets.
Chandra Bhagat Pharma Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards for its manufacturing facilities enhances its ability to access these markets, as WHO prequalification is often a prerequisite for entry into many emerging economies.
Chandra Bhagat Pharma Limited's geographic strategy demonstrates a balanced approach, with a significant portion of its exports directed towards the "Other" category (48.1%), followed by Advanced Oncology (18.3%) and Respiratory & OTC (14.3%). This diversification indicates a strategic focus on various therapeutic areas and regions, mitigating concentration risk. The company's export portfolio includes nine products across six therapeutic categories, reflecting a broad market presence.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Chandra Bhagat Pharma Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), allowing for the production of pharmaceutical formulations intended for the U.S. market. The company has also obtained necessary approvals for its formulations, enabling manufacturing through contract manufacturers. While specific details regarding approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's compliance with FDA regulations underscores its commitment to quality and regulatory standards.
Chandra Bhagat Pharma Limited ensures that its products are sourced from qualified factories with a minimum of World Health Organization Good Manufacturing Practice (WHO GMP) approvals. This adherence to WHO GMP standards facilitates access to regulated markets and underscores the company's commitment to quality manufacturing practices.
In India, Chandra Bhagat Pharma Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), authorizing the production of pharmaceutical formulations. The company also possesses necessary approvals from state drug controllers and export No Objection Certificates (NOCs), enabling the export of its products to various international markets.
As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Chandra Bhagat Pharma Limited by regulatory authorities. This absence suggests a favorable regulatory standing for the company.
Market share comparison, key differentiators, and strategic analysis
Chandra Bhagat Pharma Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products across overlapping therapeutic categories. While specific market share data is not publicly disclosed, the company's focus on critical care and healthcare products positions it to compete effectively in both domestic and international markets. The company's adherence to WHO GMP standards and its established distribution networks enhance its competitive edge.
Chandra Bhagat Pharma Limited's key differentiators include its long-standing presence in the pharmaceutical industry since 1944, a diverse product portfolio spanning various therapeutic categories, and a commitment to quality manufacturing practices as evidenced by sourcing products from WHO GMP-approved facilities. These factors contribute to the company's competitive advantages in the market.
Chandra Bhagat Pharma Limited's current strategic direction focuses on the marketing of pharmaceutical critical care and healthcare products, with an emphasis on both domestic and international markets. The company's future outlook includes expanding its product portfolio and enhancing its presence in emerging markets, leveraging its adherence to WHO GMP standards and established distribution networks.
Track record assessment, certifications to verify, and pre-order checks
Chandra Bhagat Pharma Limited demonstrates a strong track record in the pharmaceutical industry, with a history of introducing several products for the first time in India, such as Anti-Tetanus Serum, Oral Poliomyelitis Vaccine, Anti Diphtheria Sera, Streptokinase, Measles Vaccine, Meningococcal A + C Vaccine, and Human Diploid Rabies Vaccine. The company's export volume and consistency are supported by its adherence to WHO GMP standards and its established distribution networks. Reliability indicators include compliance with regulatory standards and a diverse product portfolio catering to various therapeutic areas.
Importers should verify the following certifications when considering products from Chandra Bhagat Pharma Limited:
These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from Chandra Bhagat Pharma Limited.
When conducting due diligence on Chandra Bhagat Pharma Limited, consider the following steps:
Chandra Bhagat Pharma Limited exports 9 pharmaceutical products across 6 therapeutic categories. The top exports are Immunoglobulin ($950.0K), Trastuzumab ($300.0K), Guaifenesin ($283.1K), Cyclosporine ($156.2K), Warfarin ($139.3K). Total export value is $2.0M.
Chandra Bhagat Pharma Limited's total pharmaceutical export value is $2.0M, based on 81 verified shipments recorded in Indian Customs (DGFT) data.
Chandra Bhagat Pharma Limited exports across 6 therapeutic categories. The largest are Other (48.1%, 1 products), Advanced Oncology (18.3%, 4 products), Respiratory & OTC (14.3%, 1 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
9 Products Tracked
6 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.